271 related articles for article (PubMed ID: 33707773)
1. A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome.
Erdos MR; Cabral WA; Tavarez UL; Cao K; Gvozdenovic-Jeremic J; Narisu N; Zerfas PM; Crumley S; Boku Y; Hanson G; Mourich DV; Kole R; Eckhaus MA; Gordon LB; Collins FS
Nat Med; 2021 Mar; 27(3):536-545. PubMed ID: 33707773
[TBL] [Abstract][Full Text] [Related]
2. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
[TBL] [Abstract][Full Text] [Related]
3. Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome.
Puttaraju M; Jackson M; Klein S; Shilo A; Bennett CF; Gordon L; Rigo F; Misteli T
Nat Med; 2021 Mar; 27(3):526-535. PubMed ID: 33707772
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Progerin Suppression and Lamin A Restoration Rescue Hutchinson-Gilford Progeria Syndrome.
Sánchez-López A; Espinós-Estévez C; González-Gómez C; Gonzalo P; Andrés-Manzano MJ; Fanjul V; Riquelme-Borja R; Hamczyk MR; Macías Á; Del Campo L; Camafeita E; Vázquez J; Barkaway A; Rolas L; Nourshargh S; Dorado B; Benedicto I; Andrés V
Circulation; 2021 Nov; 144(22):1777-1794. PubMed ID: 34694158
[TBL] [Abstract][Full Text] [Related]
5. Vascular Smooth Muscle-Specific Progerin Expression Accelerates Atherosclerosis and Death in a Mouse Model of Hutchinson-Gilford Progeria Syndrome.
Hamczyk MR; Villa-Bellosta R; Gonzalo P; Andrés-Manzano MJ; Nogales P; Bentzon JF; López-Otín C; Andrés V
Circulation; 2018 Jul; 138(3):266-282. PubMed ID: 29490993
[TBL] [Abstract][Full Text] [Related]
6. Activating the synthesis of progerin, the mutant prelamin A in Hutchinson-Gilford progeria syndrome, with antisense oligonucleotides.
Fong LG; Vickers TA; Farber EA; Choi C; Yun UJ; Hu Y; Yang SH; Coffinier C; Lee R; Yin L; Davies BS; Andres DA; Spielmann HP; Bennett CF; Young SG
Hum Mol Genet; 2009 Jul; 18(13):2462-71. PubMed ID: 19376814
[TBL] [Abstract][Full Text] [Related]
7. Genetic reduction of mTOR extends lifespan in a mouse model of Hutchinson-Gilford Progeria syndrome.
Cabral WA; Tavarez UL; Beeram I; Yeritsyan D; Boku YD; Eckhaus MA; Nazarian A; Erdos MR; Collins FS
Aging Cell; 2021 Sep; 20(9):e13457. PubMed ID: 34453483
[TBL] [Abstract][Full Text] [Related]
8. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment.
Villa-Bellosta R; Rivera-Torres J; Osorio FG; Acín-Pérez R; Enriquez JA; López-Otín C; Andrés V
Circulation; 2013 Jun; 127(24):2442-51. PubMed ID: 23690466
[TBL] [Abstract][Full Text] [Related]
9. Splicing-directed therapy in a new mouse model of human accelerated aging.
Osorio FG; Navarro CL; Cadiñanos J; López-Mejía IC; Quirós PM; Bartoli C; Rivera J; Tazi J; Guzmán G; Varela I; Depetris D; de Carlos F; Cobo J; Andrés V; De Sandre-Giovannoli A; Freije JM; Lévy N; López-Otín C
Sci Transl Med; 2011 Oct; 3(106):106ra107. PubMed ID: 22030750
[TBL] [Abstract][Full Text] [Related]
10. Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.
Finley J
Med Hypotheses; 2018 Sep; 118():151-162. PubMed ID: 30037605
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotide induction of progerin in human myogenic cells.
Luo YB; Mitrpant C; Adams AM; Johnsen RD; Fletcher S; Mastaglia FL; Wilton SD
PLoS One; 2014; 9(6):e98306. PubMed ID: 24892300
[TBL] [Abstract][Full Text] [Related]
12. Vascular smooth muscle cell-specific progerin expression in a mouse model of Hutchinson-Gilford progeria syndrome promotes arterial stiffness: Therapeutic effect of dietary nitrite.
Del Campo L; Sánchez-López A; Salaices M; von Kleeck RA; Expósito E; González-Gómez C; Cussó L; Guzmán-Martínez G; Ruiz-Cabello J; Desco M; Assoian RK; Briones AM; Andrés V
Aging Cell; 2019 Jun; 18(3):e12936. PubMed ID: 30884114
[TBL] [Abstract][Full Text] [Related]
13. In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice.
Koblan LW; Erdos MR; Wilson C; Cabral WA; Levy JM; Xiong ZM; Tavarez UL; Davison LM; Gete YG; Mao X; Newby GA; Doherty SP; Narisu N; Sheng Q; Krilow C; Lin CY; Gordon LB; Cao K; Collins FS; Brown JD; Liu DR
Nature; 2021 Jan; 589(7843):608-614. PubMed ID: 33408413
[TBL] [Abstract][Full Text] [Related]
14. Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach.
Rajeev M; Ratan C; Krishnan K; Vijayan M
Recent Pat Biotechnol; 2021; 15(4):266-285. PubMed ID: 34602042
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
[TBL] [Abstract][Full Text] [Related]
16. An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome.
Harhouri K; Frankel D; Bartoli C; Roll P; De Sandre-Giovannoli A; Lévy N
Nucleus; 2018 Jan; 9(1):246-257. PubMed ID: 29619863
[TBL] [Abstract][Full Text] [Related]
17. Interruption of progerin-lamin A/C binding ameliorates Hutchinson-Gilford progeria syndrome phenotype.
Lee SJ; Jung YS; Yoon MH; Kang SM; Oh AY; Lee JH; Jun SY; Woo TG; Chun HY; Kim SK; Chung KJ; Lee HY; Lee K; Jin G; Na MK; Ha NC; Bárcena C; Freije JM; López-Otín C; Song GY; Park BJ
J Clin Invest; 2016 Oct; 126(10):3879-3893. PubMed ID: 27617860
[TBL] [Abstract][Full Text] [Related]
18. Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome.
Strandgren C; Revêchon G; Sola-Carvajal A; Eriksson M
Biochem Soc Trans; 2017 Dec; 45(6):1279-1293. PubMed ID: 29127216
[TBL] [Abstract][Full Text] [Related]
19. Neuropeptide Y Enhances Progerin Clearance and Ameliorates the Senescent Phenotype of Human Hutchinson-Gilford Progeria Syndrome Cells.
Aveleira CA; Ferreira-Marques M; Cortes L; Valero J; Pereira D; Pereira de Almeida L; Cavadas C
J Gerontol A Biol Sci Med Sci; 2020 May; 75(6):1073-1078. PubMed ID: 32012215
[TBL] [Abstract][Full Text] [Related]
20. Vascular smooth muscle cell loss underpins the accelerated atherosclerosis in Hutchinson-Gilford progeria syndrome.
Hamczyk MR; Andrés V
Nucleus; 2019 Dec; 10(1):28-34. PubMed ID: 30900948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
